124 related articles for article (PubMed ID: 7591480)
1. Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75).
Pinski J; Schally AV; Yano T; Groot K; Srkalovic G; Serfozo P; Reissmann T; Bernd M; Deger W; Kutscher B
Int J Pept Protein Res; 1995 May; 45(5):410-7. PubMed ID: 7591480
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of biological activities of new LH-RH antagonists (T-series) in male and female rats.
Pinski J; Yano T; Janaky T; Nagy A; Juhasz A; Bokser L; Groot K; Schally AV
Int J Pept Protein Res; 1993 Jan; 41(1):66-73. PubMed ID: 8436447
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75).
Gonzalez-Barcena D; Vadillo Buenfil M; Garcia Procel E; Guerra-Arguero L; Cardenas Cornejo I; Comaru-Schally AM; Schally AV
Eur J Endocrinol; 1994 Sep; 131(3):286-92. PubMed ID: 7921214
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of a highly potent antagonist of LH releasing hormone (SB-75) on the pituitary gonadal axis in the intact and castrated rat.
Ayalon D; Farhi Y; Comaru-Schally AM; Schally AV; Eckstein N; Vagman I; Limor R
Neuroendocrinology; 1993 Aug; 58(2):153-9. PubMed ID: 8264861
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.
Halmos G; Schally AV; Pinski J; Vadillo-Buenfil M; Groot K
Proc Natl Acad Sci U S A; 1996 Mar; 93(6):2398-402. PubMed ID: 8637885
[TBL] [Abstract][Full Text] [Related]
6. Antiovulatory doses of antagonists of LH-RH inhibit LH and progesterone but not FSH and estradiol release.
Kovács M; Koppán M; Mezö I; Teplán I; Flerkó B
J Neuroendocrinol; 1993 Dec; 5(6):603-8. PubMed ID: 8680431
[TBL] [Abstract][Full Text] [Related]
7. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).
Bokser L; Srkalovic G; Szepeshazi K; Schally AV
Neuroendocrinology; 1991 Aug; 54(2):136-45. PubMed ID: 1662786
[TBL] [Abstract][Full Text] [Related]
8. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer.
Gonzalez-Barcena D; Vadillo-Buenfil M; Gomez-Orta F; Fuentes Garcia M; Cardenas-Cornejo I; Graef-Sanchez A; Comaru-Schally AM; Schally AV
Prostate; 1994; 24(2):84-92. PubMed ID: 7508623
[TBL] [Abstract][Full Text] [Related]
9. Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects.
Bajusz S; Kovacs M; Gazdag M; Bokser L; Karashima T; Csernus VJ; Janaky T; Guoth J; Schally AV
Proc Natl Acad Sci U S A; 1988 Mar; 85(5):1637-41. PubMed ID: 3278323
[TBL] [Abstract][Full Text] [Related]
10. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men.
Behre HM; Klein B; Steinmeyer E; McGregor GP; Voigt K; Nieschlag E
J Clin Endocrinol Metab; 1992 Aug; 75(2):393-8. PubMed ID: 1639941
[TBL] [Abstract][Full Text] [Related]
11. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the antigonadotropic activity of three GnRH antagonists (Nal-Glu, Antide and Cetrorelix) in a non-human primate model (Macaca fascicularis).
Weinbauer GF; Nieschlag E
Andrologia; 1993; 25(3):141-7. PubMed ID: 8517553
[TBL] [Abstract][Full Text] [Related]
13. Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75.
Pinski J; Yano T; Miller G; Schally AV
Prostate; 1992; 20(3):213-24. PubMed ID: 1533453
[TBL] [Abstract][Full Text] [Related]
14. Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men.
Behre HM; Böckers A; Schlingheider A; Nieschlag E
Clin Endocrinol (Oxf); 1994 Feb; 40(2):241-8. PubMed ID: 8137524
[TBL] [Abstract][Full Text] [Related]
15. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.
Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
Cancer Res; 1990 Jun; 50(12):3716-21. PubMed ID: 2160323
[TBL] [Abstract][Full Text] [Related]
16. Development of radioimmunoassay for a potent luteinizing hormone-releasing hormone antagonist. Evaluation of serum levels after injection of [Ac-3-(2-naphthyl)-D-Ala1, D-Phe(pCl)2, 3-(3-pyridyl)-D-Ala3, D-Cit6, D-Ala10] LHRH.
Csernus VJ; Szende B; Groot K; Redding TW; Schally AV
Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):111-8. PubMed ID: 2110458
[TBL] [Abstract][Full Text] [Related]
17. Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone.
Reissmann T; Hilgard P; Harleman JH; Engel J; Comaru-Schally AM; Schally AV
J Cancer Res Clin Oncol; 1992; 118(1):44-9. PubMed ID: 1530849
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
Yano T; Pinski J; Halmos G; Szepeshazi K; Groot K; Schally AV
Proc Natl Acad Sci U S A; 1994 Jul; 91(15):7090-4. PubMed ID: 7518926
[TBL] [Abstract][Full Text] [Related]
19. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.
Bajusz S; Csernus VJ; Janaky T; Bokser L; Fekete M; Schally AV
Int J Pept Protein Res; 1988 Dec; 32(6):425-35. PubMed ID: 2469662
[TBL] [Abstract][Full Text] [Related]
20. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.
Pinski J; Lamharzi N; Halmos G; Groot K; Jungwirth A; Vadillo-Buenfil M; Kakar SS; Schally AV
Endocrinology; 1996 Aug; 137(8):3430-6. PubMed ID: 8754771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
